>
网站首页期刊介绍通知公告编 委 会投稿须知电子期刊广告合作联系我们
最新消息:
白花蛇舌草解毒健脾方对原发性肝癌晚期患者肿瘤相关指标及疼痛的影响
作者:蔡林  廖伯年 
单位:川北医学院附属医院中医科, 重庆 637000
关键词:白花蛇舌草解毒健脾方 原发性肝癌晚期 肿瘤标志物 
分类号:R451
出版年·卷·期(页码):2017·36·第一期(44-47)
摘要:

目的:探讨中药白花蛇舌草解毒健脾方对原发性肝癌晚期患者肿瘤相关指标以及疼痛的影响。方法:选择2014年5月至2015年12月于我院治疗的80例原发性肝癌晚期患者,根据相近入院时间随机分为研究组和对照组,每组40例,对照组实施常规支持治疗,研究组在常规支持治疗基础上,给予自拟白花蛇舌草解毒健脾方,辅以辨证加减治疗。比较两组患者的疼痛评分(VAS)及血清肿瘤相关指标。结果:治疗后两组VAS均较治疗前显著下降(P<0.05),研究组VAS低于对照组,但差异无统计学意义(P>0.05)。治疗后研究组血清中甲胎蛋白、癌胚抗原、糖抗原199水平均显著低于治疗前及对照组(P<0.05),血清结缔组织生长因子、血管内皮生长因子及缺氧诱导因子-1α水平均显著低于治疗前及对照组(P<0.05)。两组不良反应比较,差异无统计学意义(P>0.05)。结论:白花蛇舌草解毒健脾方能够显著缓解原发性肝癌晚期患者的疼痛,抑制肿瘤细胞的增殖,且毒副作用小,安全性高,临床可推广使用。

Objective:To investigate the effects of Hedyotis diffusa willd detoxification Spleen Prescription on tumor related index and pain in patients with advanced primary liver cancer.Methods:Eighty patients with advanced primary liver cancer admitted to our hospital during May.2014 to Dec.2015 were divided into the control group and the observation group,40 in each.The control group was treated with general supportive care,and on the base,the observation group was treated with Hedyotis diffusa willd detoxification Spleen Prescription,and supplemented syndrome treating.The VAS and the serum tumor related index levels were compared between the two groups.Results:The VAS of the two groups were all significantly reduced after treatment(P<0.05),but there was no difference between the two groups(P<0.05).And after treatment,the levels of serum Alpha fetoprotein,carcinoembryonic antigen and carbohydrate antigen 199 in the observation group were significantly lower than those in control group and before treatedment (P<0.05).After treatment,the levels of serum connective tissue growth factor and vascular endothelial growth factor (VEGF) and hypoxia inducible factor-1 alpha (HIF-1 alpha) in the observation group were significantly lower than those before treatment (P<0.05), and the observation group was significantly lower than those in control group (P<0.05).Adverse reactions of the two groups were not statistically significant (P>0.05).Conclusion:Hedyotis diffusa willd detoxification Spleen Prescription can significantly alleviate the pain of patients with advanced primary liver cancer,inhibit the proliferation of tumor cells,and there is little toxic side effects,it is safe and should be clinically widely used.

参考文献:

[1] 吴孟超.原发性肝癌在中国的治疗和研究现状[J].成都医学院学报,2012,7(2):161-162.
[2] NI C Y, YANG Y,CHANG Y Q, et al.Fast-track surgery improves postoperative recovery in patients undergoing partial hepatectomy for primary liver cancer:A prospective randomized controlled trial[J].Eur J Surg Oncol,2013,39(6):542-547.
[3] JÁNOS F,GABRIELLA L.Silymarin in the prevention and treatment of liver diseases and primary liver cancer[J].Curr Pharm Biotech,2012,13(1):210-217.
[4] 中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-946.
[5] WANG Y,O'CONNOR M,XU Y,et al.Symptom clusters in Chinese patients with primary liver cancer[J].Oncol Nurs Forum,2012,39(6):468-79.
[6] 邓宝贵,全小明,林雪梅.加味双柏散外敷预防原发性肝癌病人围介入期肝区疼痛的疗效观察[J].护理研究,2012,26(7):613-614.
[7] 汪猛,秦凯健,杨梦琪,等.原发性肝癌的中医药诊治研究进展[J].中医药导报,2015,21(3):49-52.
[8] 何立丽,吕文良,孙桂芝.中药提取物抗原发性肝癌的研究进展[J].中华中医药杂志,2014,29(4):1175-1178.
[9] 任红艳,方肇勤.方肇勤治疗原发性肝癌撷萃[J].中国中医基础医学杂志,2014,20(1):83-83.
[10] 张欣,张国梁.血清肿瘤标记物联合检测对原发性肝癌的诊断价值[J].中国实验诊断学,2012,16(5):848-850.
[11] CHEN Q W, CHENG C S, CHEN H,et al.Effectiveness and complications of ultrasound guided fine needle aspiration for primary liver cancer in a Chinese population with serum α-fetoprotein levels ≤ 200ng/ml-a study based on 4,312 patients[J].PLoS One,2013,9(8):e101536-e101536.
[12] 刘英平,潘在兴.甲胎蛋白与癌胚抗原在原发性肝癌与转移性肝癌鉴别诊断中的意义分析[J].中国实验诊断学,2013,17(12):2269-2270.
[13] WANG L,FENG F,MA Z.Novel electrochemical redox-active species:one-step synthesis of polyaniline derivative-Au/Pd and its application for multiplexed immunoassay[J].Sci Rep,2015,19(10):3127-3145.
[14] 姚娟,黄俊星,于鸿,等.肿瘤转移相关标志物在食管鳞状细胞癌中的表达及意义[J].江苏医药,2014,40(1):31-34.
[15] 石燕,陈丽,王治宽,等.Ⅰ~Ⅲ期胃癌中VEGF、HIF-1α和TGF-β1表达的临床意义及其预后价值[J].临床肿瘤学杂志,2013,18(4):310-316.

服务与反馈:
文章下载】【发表评论】【查看评论】【加入收藏
提示:您还未登录,请登录!点此登录
您是第 145674 位访问者


copyright ©《东南大学学报(医学版)》编辑部
联系电话:025-87232483 83272481
电子邮件:
bjb@pub.seu.edu.cn

苏ICP备09058364